Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) Return on Equity (2018 - 2025)

Historic Return on Equity for Inmune Bio (INMB) over the last 8 years, with Q3 2025 value amounting to 1.89%.

  • Inmune Bio's Return on Equity fell 7900.0% to 1.89% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.89%, marking a year-over-year decrease of 7900.0%. This contributed to the annual value of 1.23% for FY2024, which is 6100.0% down from last year.
  • Latest data reveals that Inmune Bio reported Return on Equity of 1.89% as of Q3 2025, which was down 7900.0% from 1.92% recorded in Q2 2025.
  • In the past 5 years, Inmune Bio's Return on Equity ranged from a high of 0.09% in Q1 2021 and a low of 1.92% during Q2 2025
  • For the 5-year period, Inmune Bio's Return on Equity averaged around 0.77%, with its median value being 0.49% (2023).
  • As far as peak fluctuations go, Inmune Bio's Return on Equity surged by 100bps in 2021, and later crashed by -7900bps in 2025.
  • Quarter analysis of 5 years shows Inmune Bio's Return on Equity stood at 0.35% in 2021, then decreased by -21bps to 0.42% in 2022, then crashed by -75bps to 0.73% in 2023, then tumbled by -65bps to 1.2% in 2024, then tumbled by -57bps to 1.89% in 2025.
  • Its last three reported values are 1.89% in Q3 2025, 1.92% for Q2 2025, and 1.34% during Q1 2025.